These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil]. Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824 [TBL] [Abstract][Full Text] [Related]
4. Substituting for cerivastatin (Baycol). Med Lett Drugs Ther; 2001 Sep; 43(1113):79-80. PubMed ID: 11581579 [No Abstract] [Full Text] [Related]
5. Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen. Marsà Carretero M; Alos Manrique C; Valles Callol JA Br J Gen Pract; 2002 Mar; 52(476):235-6. PubMed ID: 12030671 [No Abstract] [Full Text] [Related]
6. [Rhabdomyolysis, acute renal failure and use of cerivastatin combined with gemfibrozil. New evidence]. SantaCruz PL; González A; León ME; Fernández MY Nefrologia; 2002; 22(3):301-2. PubMed ID: 12123135 [No Abstract] [Full Text] [Related]
8. Baycol withdrawn from market. SoRelle R Circulation; 2001 Aug; 104(8):E9015-6. PubMed ID: 11521677 [No Abstract] [Full Text] [Related]
9. Bayer is forced to release documents over withdrawal of cerivastatin. Marwick C BMJ; 2003 Mar; 326(7388):518. PubMed ID: 12623898 [No Abstract] [Full Text] [Related]
10. [Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination]. Sirvent AE; Cabezuelo JB; Enríquez R; Amorós F; González C; Reyes A Nefrologia; 2001; 21(5):497-500. PubMed ID: 11795020 [TBL] [Abstract][Full Text] [Related]
11. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report. Ozdemir O; Boran M; Gökçe V; Uzun Y; Koçak B; Korkmaz S Angiology; 2000 Aug; 51(8):695-7. PubMed ID: 10959522 [TBL] [Abstract][Full Text] [Related]
12. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Chang JT; Staffa JA; Parks M; Green L Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925 [TBL] [Abstract][Full Text] [Related]
13. Dual hepatic metabolism of cerivastatin--clarifications. Guyton JR; Dujovne CA; Illingworth DR Am J Cardiol; 1999 Aug; 84(4):497. PubMed ID: 10468102 [No Abstract] [Full Text] [Related]
14. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction. Kind AH; Zakowski LJ; McBride PE WMJ; 2002; 101(7):53-6. PubMed ID: 12426921 [TBL] [Abstract][Full Text] [Related]
16. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]. Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751 [TBL] [Abstract][Full Text] [Related]
17. [We, the Italian physicians, and statins]. Bobbio M Ital Heart J Suppl; 2001 Nov; 2(11):1149-54. PubMed ID: 11775405 [TBL] [Abstract][Full Text] [Related]
18. Rhabdomyolysis and cerivastatin: was it a problem of dose? Kalaria D; Wassenaar W CMAJ; 2002 Oct; 167(7):737. PubMed ID: 12389822 [No Abstract] [Full Text] [Related]
19. Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". Piorkowski JD JAMA; 2004 Dec; 292(21):2655-7; discussion 2658-9. PubMed ID: 15572725 [No Abstract] [Full Text] [Related]
20. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. McAdams M; Staffa J; Dal Pan G Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]